Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab long-term extension trial in participants with advanced tumors
NL-OMON52613Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of pembrolizumab in cancer and Nonhematologic neoplasms (3 arms), sponsored by Merck & Co. Primary endpoint: Overall survival. Started Dec 2018; status: recruiting.
02
Drugs
03
Conditions
cancerNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON52613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52613.